10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2023

☐          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File No. 001-39256

RESEARCH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	11-3797644
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
Address not applicable1	N/A
(Address of principal executive offices)	(Zip Code)

(310) 477-0354

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each Exchange on which registered
Common stock, $0.001 par value	RSSS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  þ      No  ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer þ	Smaller reporting company þ
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Title of Class	Number of Shares Outstanding on May 5, 2023
Common Stock, $0.001 par value	29,500,764

¹ In November 2019, we became a fully remote company. Accordingly, we do not currently have principal executive offices.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION	3
Item 1. Condensed Consolidated Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3. Quantitative and Qualitative Disclosures About Market Risk	32
Item 4. Controls and Procedures	32
PART II — OTHER INFORMATION	33
Item 1A. Risk Factors	33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 6. Exhibits	34
SIGNATURES	35

2

PART 1 — FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	March 31,
	2023		June 30,
	(unaudited)		2022
Assets
Current assets:
Cash and cash equivalents	$	12,132,899	$	10,603,175
Accounts receivable, net of allowance of $49,670 and $94,144, respectively		6,797,240		5,251,545
Prepaid expenses and other current assets		398,726		276,026
Prepaid royalties		798,892		846,652
Total current assets		20,127,757		16,977,398
Other assets:
Property and equipment, net of accumulated depreciation of $868,324 and $840,996, respectively		53,766		47,985
Intangible assets, net of accumulated amortization of $11,046 and $0, respectively		430,788		—
Deposits and other assets		997		893
Total assets	$	20,613,308	$	17,026,276
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	7,696,205	$	6,604,032
Deferred revenue		6,524,570		5,538,526
Total current liabilities		14,220,775		12,142,558
Commitments and contingencies
Stockholders’ equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding		—		—
Common stock; $0.001 par value; 100,000,000 shares authorized; 29,500,764 and 27,075,648 shares issued and outstanding, respectively		29,501		27,076
Additional paid-in capital		29,386,169		28,072,855
Accumulated deficit		(22,898,395)		(23,094,272)
Accumulated other comprehensive loss		(124,742)		(121,941)
Total stockholders’ equity		6,392,533		4,883,718
Total liabilities and stockholders’ equity	$	20,613,308	$	17,026,276

See notes to condensed consolidated financial statements

3

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Revenue:
Platforms	$	2,249,632	$	1,786,224	$	6,379,871	$	4,900,927
Transactions		8,092,794		6,971,128		21,363,864		19,471,216
Total revenue		10,342,426		8,757,352		27,743,735		24,372,143
Cost of revenue:
Platforms		268,630		219,051		752,176		696,375
Transactions		6,046,523		5,299,804		16,211,211		14,939,236
Total cost of revenue		6,315,153		5,518,855		16,963,387		15,635,611
Gross profit		4,027,273		3,238,497		10,780,348		8,736,532
Operating expenses:
Selling, general and administrative		3,875,802		3,573,454		10,766,537		9,912,690
Depreciation and amortization		18,332		4,988		30,486		12,144
Total operating expenses		3,894,134		3,578,442		10,797,023		9,924,834
Income (loss) from operations		133,139		(339,945)		(16,675)		(1,188,302)
Other income		104,331		237		218,095		777
Income (loss) from operations before provision for income taxes		237,470		(339,708)		201,420		(1,187,525)
Provision for income taxes		(628)		(822)		(5,543)		(6,592)
Net income (loss)		236,842		(340,530)		195,877		(1,194,117)
Other comprehensive income (loss):
Foreign currency translation		(4,149)		1,609		(2,801)		(1,181)
Comprehensive income (loss)	$	232,693	$	(338,921)	$	193,076	$	(1,195,298)
Basic income (loss) per common share:
Net income (loss) per share	$	0.01	$	(0.01)	$	0.01	$	(0.05)
Weighted average common shares outstanding		26,929,314		26,512,195		26,820,557		26,392,949
Diluted income (loss) per common share:
Net income (loss) per share	$	0.01	$	(0.01)	$	0.01	$	(0.05)
Weighted average common shares outstanding		29,791,719		26,512,195		28,837,774		26,392,949

See notes to condensed consolidated financial statements

4

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Nine Months Ended March 31, 2023

(Unaudited)

				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity
Balance, December 31, 2022	29,154,737	$	29,155	$	28,874,383	$	(23,135,237)	$	(120,593)	$	5,647,708
Fair value of vested stock options	—		—		37,236		—		—		37,236
Fair value of vested restricted common stock	332,500		333		442,890		—		—		443,223
Forfeited restricted common stock	(65,165)		(65)		65		—		—		—
Repurchase of common stock	(12,785)		(13)		(25,814)		—		—		(25,827)
Common stock issued upon exercise of stock options	91,477		91		57,409		—		—		57,500
Net income for the period	—		—		—		236,842		—		236,842
Foreign currency translation	—		—		—		—		(4,149)		(4,149)
Balance, March 31, 2023	29,500,764	$	29,501	$	29,386,169	$	(22,898,395)	$	(124,742)	$	6,392,533
Balance, July 1, 2022	27,075,648	$	27,076	$	28,072,855	$	(23,094,272)	$	(121,941)	$	4,883,718
Fair value of vested stock options	—		—		338,973		—		—		338,973
Fair value of vested restricted common stock	2,354,834		2,355		923,195		—		—		925,550
Forfeited restricted common stock	(65,165)		(65)		65		—		—		—
Fair value of vested unrestricted common stock	36,509		36		68,236		—		—		68,272
Repurchase of common stock	(38,585)		(38)		(74,518)		—		—		(74,556)
Common stock issued upon exercise of stock options	137,523		137		57,363		—		—		57,500
Net income for the period	—		—		—		195,877		—		195,877
Foreign currency translation	—		—		—		—		(2,801)		(2,801)
Balance, March 31, 2023	29,500,764	$	29,501	$	29,386,169	$	(22,898,395)	$	(124,742)	$	6,392,533

See notes to condensed consolidated financial statements

5

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Nine Months Ended March 31, 2022

(Unaudited)

				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity
Balance, December 31, 2021	26,817,056	$	26,817	$	27,475,741	$	(22,315,475)	$	(122,367)	$	5,064,716
Fair value of vested stock options	—		—		296,782		—		—		296,782
Fair value of vested restricted common stock	42,214		42		102,410		—		—		102,452
Repurchase of common stock	(6,086)		(6)		(14,235)		—		—		(14,241)
Common stock issued upon exercise of stock options	147,660		148		66,869		—		—		67,017
Net loss for the period	—		—		—		(340,530)		—		(340,530)
Foreign currency translation	—		—		—		—		1,609		1,609
Balance, March 31, 2022	27,000,844	$	27,001	$	27,927,567	$	(22,656,005)	$	(120,758)	$	5,177,805
Balance, July 1, 2021	26,498,215	$	26,498	$	26,982,052	$	(21,461,888)	$	(119,577)	$	5,427,085
Fair value of vested stock options	—		—		424,450		—		—		424,450
Fair value of vested restricted common stock	293,211		293		446,140		—		—		446,433
Repurchase of common stock	(33,402)		(34)		(82,019)		—		—		(82,053)
Common stock issued upon exercise of stock options	192,820		194		97,494		—		—		97,688
Common stock issued upon exercise of warrants	50,000		50		59,450		—		—		59,500
Net loss for the period	—		—		—		(1,194,117)		—		(1,194,117)
Foreign currency translation	—		—		—		—		(1,181)		(1,181)
Balance, March 31, 2022	27,000,844	$	27,001	$	27,927,567	$	(22,656,005)	$	(120,758)	$	5,177,805

See notes to condensed consolidated financial statements

6

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	March 31,
	2023		2022
Cash flow from operating activities:
Net income (loss)	$	195,877	$	(1,194,117)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		30,486		12,144
Fair value of vested stock options		338,973		424,450
Fair value of vested restricted common stock		925,550		446,433
Fair value of vested unrestricted common stock		68,272		—
Changes in operating assets and liabilities:
Accounts receivable		(1,545,695)		(904,915)
Prepaid expenses and other current assets		(122,700)		(67,984)
Prepaid royalties		47,760		(54,287)
Accounts payable and accrued expenses		947,789		397,088
Deferred revenue		986,044		538,477
Net cash provided by (used in) operating activities		1,872,356		(402,711)
Cash flow from investing activities:
Purchase of property and equipment		(29,976)		(34,251)
Payment for non-refundable deposit for asset acquisition		(297,450)		—
Net cash used in investing activities		(327,426)		(34,251)
Cash flow from financing activities:
Proceeds from the exercise of stock options		57,500		97,688
Proceeds from the exercise of warrants		—		59,500
Common stock repurchase		(74,556)		(82,053)
Net cash provided by (used in) financing activities		(17,056)		75,135
Effect of exchange rate changes		1,850		(1,989)
Net increase (decrease) in cash and cash equivalents		1,529,724		(363,816)
Cash and cash equivalents, beginning of period		10,603,175		11,004,337
Cash and cash equivalents, end of period	$	12,132,899	$	10,640,521
Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	5,543	$	6,592
Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$	144,384	$	—

See notes to condensed consolidated financial statements

7

RESEARCH SOLUTIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Nine Months Ended March 31, 2023 and 2022 (Unaudited)

Note 1.  Organization, Nature of Business and Basis of Presentation

Organization

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with three wholly owned subsidiaries: Reprints Desk, Inc., (“Reprints Desk”) a Delaware corporation, Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Nature of Business

We provide two service offerings to our customers: a cloud-based software-as-a-service (“SaaS”) research platform (“Platforms”) typically sold via annual auto-renewing license agreements and the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via the Platform. When customers utilize the Platform to purchase Transactions it is packaged as a single solution that enables life science and other research intensive organizations to accelerate their research and development activities with faster, access and management of STM articles used throughout the intellectual property development lifecycle. The Platform typically delivers a ROI to the customer via more effectively managing Transaction costs and saving researchers time during the research process.

Platforms

Our cloud-based SaaS research Platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

Additional functionality has recently been added to our Platform in the form of interactive app-like components. An alternative to manual data filtering, identification and extraction, the apps are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We continue to develop new apps in order to build an ecosystem of apps. Together, these apps will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

Transactions

Our Platform provides our customers with a single source to the universe of published STM content that includes over 80 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour; in many cases under one minute. This service is generally known in the industry

8

as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

Principles of Consolidation

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2022 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Note 2.   Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, impairment related to intangible assets and realization of deferred tax assets.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

9

The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2023 and June 30, 2022.

The following table summarizes vendor concentrations:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Vendor A	23	%	22	%	22	%	21	%
Vendor B	14	%	13	%	13	%	13	%

Revenue Recognition

The Company accounts for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

10

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Revenue by Geographical Region

The following table summarizes revenue by geographical region:

	Three Months Ended
	March 31,
	2023				2022
United States	$	5,892,424	57.0	%	$	5,027,965	57.4	%
Europe		3,530,469	34.1	%		3,159,984	36.1	%
Rest of World		919,533	8.9	%		569,403	6.5	%
Total	$	10,342,426	100	%	$	8,757,352	100	%

	Nine Months Ended
	March 31,
	2023				2022
United States	$	15,997,407	57.7	%	$	14,222,605	58.4	%
Europe		9,503,235	34.3	%		8,488,722	34.8	%
Rest of World		2,243,093	8.1	%		1,660,816	6.8	%
Total	$	27,743,735	100	%	$	24,372,143	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:

	As of March 31, 2023				As of June 30, 2022
United States	$	4,041,180	59.5	%	$	3,255,976	62.0	%
Europe		2,020,602	29.7	%		1,665,111	31.7	%
Rest of World		735,458	10.8	%		330,458	6.3	%
Total	$	6,797,240	100	%	$	5,251,545	100	%

Deferred Revenue

Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer.

Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

11

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

Foreign Currency

The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gain of $72,547 and $84,210 for the three and nine months ended March 31, 2023, respectively and losses of $29,394 and $52,619 for the three and nine months ended March 31, 2022, respectively. Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held in accounts at financial institutions located in Europe.

The following table summarizes the exchange rates used:

	Nine Months Ended		Year Ended
	March 31,		June 30,
	2023	2022	2023	2021
Period end Euro : US Dollar exchange rate	1.09	1.11	1.05	1.19
Average period Euro : US Dollar exchange rate	1.03	1.15	1.13	1.19
Period end GBP : US Dollar exchange rate	1.24	1.31	1.21	1.38
Average period GBP : US Dollar exchange rate	1.19	1.36	1.34	1.34
Period end Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05
Average period Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted

12

earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2023 potentially dilutive securities include options to acquire 2,925,574 shares of common stock and unvested restricted common stock of 2,528,187. At March 31, 2022 potentially dilutive securities include options to acquire 3,249,617 shares of common stock and unvested restricted common stock of 364,675. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2022 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three and nine months ended March 31, 2023, the calculation of diluted earnings per share include unvested restricted common stock, stock options and warrants, calculated under the treasury stock method.  

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Note 3.   Line of Credit

The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 28, 2024, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2023. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and 5.0%. The interest rate on the line of credit was 9% as of March 31, 2023. The line of credit is secured by the Company’s consolidated assets.

Pursuant to the Amended and Restated Loan and Security Agreement dated October 31, 2017 among the Company, Reprints Desk, Inc. and SVB (the “SVB LSA”), the Company was required to direct account debtors to deliver or transmit all proceeds of accounts remitted to the Company and its subsidiaries into a lockbox account as specified by SVB, and to maintain its and its subsidiaries’ primary operating and other deposit accounts with SVB.  In compliance with the foregoing covenants the Company and its subsidiaries maintained with SVB substantially all of the dollar value of the Company’s and its subsidiaries’ accounts. At February 28, 2023, the Company held cash at SVB of $10,832,880, of which we estimate $9,738,292 was in excess of government insured limits.    

On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank, N.A. (“SVB Bridge Bank”). On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors’ insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 14, 2023, the Company was able to access its full deposits with SVB Bridge Bank. At March 31, 2023, the

13

Company held cash at SVB Bridge Bank of $10,474,449, of which we estimate $9,406,136 was in excess of government insured limits.

There were no outstanding borrowings under the line as of March 31, 2023 and June 30, 2022, respectively. As of March 31, 2023, there was approximately $2,500,000 of available credit.

SVB Bridge Bank agreed that the Company can lower its cash balance threshold requirement associated with the SVB LSA, reducing the required balances of its and its subsidiaries’ primary operating and other accounts with SVB, and the Company continues to evaluate the SVB LSA. At March 31, 2023, the Company also held cash at Bank of America, N.A. of $750,000 and at PNC Bank, N.A. of $905,510. The Company continues to re-allocate its cash position across all three banks and explore an overall banking diversification strategy as well as additional access to lending facilities.

Note 4.   Stockholders’ Equity

Stock Options

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 17, 2020, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 2,374,513 to 3,374,513. On November 17, 2021, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 3,374,513 to 6,874,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of March 31, 2023, there were 1,495,927 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

14

The following table summarizes vested and unvested stock option activity:

	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2022	3,182,872	$	1.79	2,999,974	$	1.75	182,898	$	2.49
Granted	200,000		2.15	—		—	200,000		2.15
Options vesting	—		—	309,486		2.27	(309,486)		2.27
Exercised	(307,298)		1.31	(307,298)		1.31	—		—
Forfeited	(150,000)		1.81	(147,917)		1.78	(2,083)		3.92
Repurchased	—		—	—		—	—		—
Outstanding at March 31, 2023	2,925,574	$	1.87	2,854,245	$	1.85	71,329	$	2.46

The weighted average remaining contractual life of all options outstanding as of March 31, 2023 was 5.71 years. The remaining contractual life for options vested and exercisable at March 31, 2023 was 5.65 years. Furthermore, the aggregate intrinsic value of options outstanding and of options vested and exercisable as of March 31, 2023 was $1,060,516, in each case based on the fair value of the Company’s common stock on March 31, 2023.

During the nine months ended March 31, 2023, the Company granted 200,000 options to directors with a fair value of $222,000 which, due to immediate vesting, were fully expensed at the time of grant. The total fair value of options that vested during the nine months ended March 31, 2023 was $338,973 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of March 31, 2023, the amount of unvested compensation related to stock options was $92,793 which will be recorded as an expense in future periods as the options vest. During the nine months ended March 31, 2023, the Company issued 137,523 net shares of common stock upon the exercise of options underlying 307,298 shares of common stock, resulting in net cash proceeds of $57,500.

The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2023 and 2022.

	Nine Months Ended
	March 31,
	2023		2022
Expected dividend yield	—	%	—	%
Risk-free interest rate	3.76	%	0.92 - 1.81	%
Expected life (in years)	5		5 - 6
Expected volatility	56	%	56	%

15

Additional information regarding stock options outstanding and exercisable as of March 31, 2023 is as follows:

	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	2.68	225,000
	0.77	25,000	1.39	25,000
	0.80	16,000	2.39	16,000
	0.90	15,000	2.35	15,000
	1.00	15,000	1.95	15,000
	1.05	305,000	3.40	305,000
	1.09	40,000	3.15	40,000
	1.10	105,000	2.25	105,000
	1.20	274,000	4.30	274,000
	1.59	25,000	5.12	25,000
	1.80	54,550	0.48	54,550
	1.85	16,000	0.14	16,000
	1.95	200,000	5.26	200,000
	2.10	238,767	8.87	238,767
	2.13	216,708	7.64	213,922
	2.15	200,000	9.70	200,000
	2.17	35,955	8.12	23,970
	2.19	5,000	8.81	2,083
	2.40	302,833	5.63	302,833
	2.43	61,250	8.18	51,250
	2.45	163,000	7.35	149,416
	2.49	78,435	7.17	75,076
	2.50	20,000	6.13	20,000
	2.64	30,882	8.35	18,015
	2.67	33,194	8.47	19,363
	2.99	8,000	7.12	8,000
	3.13	208,000	6.62	208,000
	3.50	8,000	6.87	8,000
	Total	2,925,574		2,854,245

Restricted Common Stock

Prior to July 1, 2022, the Company issued 2,829,758 shares of restricted common stock to employees valued at $4,024,308, of which 2,215,342 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $3,060,652 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 400,092 at June 30, 2022, with an aggregate fair value of $775,453.

16

During the nine months ended March 31, 2023, the Company issued an additional 2,354,834 shares of restricted stock to employees with an aggregate fair value of $3,478,878. Of this amount, 229,834 shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met and 25,000 shares vest over a four year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of these stock awards was $503,478 based on the market price of our common stock price ranging from $1.94 to $2.22 per share on the date of grant, which will be amortized over the range of three and four-year vesting periods. The remaining 2,100,000 shares were granted, under the 2017 Plan, as restricted stock awards to key management in accordance with its long-term equity bonus program (the “LTEBP”). The LTEBP replaces the previous restricted stock compensation program for executives. It spans 5 years and is designed to better serve stockholder interests by aligning key executive compensation with stockholder value.  Awards under the LTEBP will vest as follows, upon the 30-day volume weighted average price (VWAP) of our common stock reaching the following targets:

•20% at a 30-day VWAP of $3.00 per share;

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

Upon a change of control vesting will accelerate with respect to that portion of the award that would vest if the target 30-day VWAP was achieved at the level above the per share price in such change of control transaction. For example, if we granted an award of 100,000 shares under the LTEBP, 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.00 per share, and 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.75 per share. If the per share price in a change of control transaction was $5.00 per share, vesting would accelerate for 40,000 shares under the same award (i.e. the number of shares that would vest for our stock price achieving a 30-day VWAP of $5.25 per share, pursuant to a tier round up provision in the Plan effective upon a change in control). As a condition to receiving awards under the LTEBP, recipients will be required to hold at least 75% of all vested shares during the term of their employment. Applicable target 30-day VWAPs must be achieved within 5 years following the grant of awards under the LTEBP, and all unvested awards under the LTEBP will be forfeited upon expiration of such 5-year period. Recipients will also forfeit unvested awards in the event their service with our company terminates for any reason.

As the vesting of the 2,100,000 shares of restricted common stock under the LTEBP is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value to be $2,975,400, computed using the Monte Carlo simulations on a binomial model with the assistance of a valuation specialist with a derived service period ranging from 1.36 to 2.59 years. The total fair value of restricted common stock vesting and expenses related to amortization of the fair value of the LTEBP program during the nine months ended March 31, 2023 was $925,549 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of March 31, 2023, the amount of unvested compensation related to issuances of restricted common stock was $3,204,829, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. When calculating net loss per share, the 2,528,187 shares are considered antidilutive and are excluded from that calculation.

17

The following table summarizes restricted common stock activity:

				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2022	400,092	$	775,453	$	2.38
Granted	2,354,834		3,478,878		1.48
Vested	(161,574)		(925,549)		2.49
Forfeited	(65,165)		(123,953)		2.15
Non-vested, March 31, 2023	2,528,187	$	3,204,829	$	1.54

Common Stock Repurchases

Effective as of February 9, 2021, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2021 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The Compensation Committee of our Board of Directors subsequently approved the extension of the repurchases under the same terms through the end of fiscal year 2023. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. As of June 30, 2022, $255,345 remained under the current authorization to repurchase our outstanding common stock from our employees.

During the nine months ended March 31, 2023, the Company repurchased 38,585 shares of our common stock from employees at an average market price of approximately $1.93 per share for an aggregate amount of $74,556. As of March 31, 2023, $180,789 remains under the current authorization to repurchase our outstanding common stock from our employees.

Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

Note 5.  Acquisition

On September 28, 2022, Reprints Desk entered into an asset purchase agreement with FIZ Karlsruhe – Leibniz-Institut für Informationsinfrastruktur GmbH (“FIZ”). FIZ delivers STM content pursuant to various contracts with its customers through its AutoDoc platform. FIZ has agreed to assign and transfer to Reprints Desk certain of these contracts effective January 1, 2023 (the “Sold Contracts”).  

On September 30, 2022, Reprints Desk made a non-refundable payment of $297,450 (€300,000) (the “Base Amount”) as initial consideration for the asset purchase. On March 31, 2023, Reprints Desk recorded $95,689 in contingent consideration for customers that have their Sold Contracts assumed by Reprints Desk in comparison to the trailing twelve months of revenue of all Sold Contracts (the “Base Amount Plus”). On March 31, 2023, $48,695 in contingent consideration was recorded for customers that placed an order and have consented to have their contract assumed by Reprints Desk (the “Bonus Amount”). The Bonus Amount is based upon the collectable service fee that FIZ would have received from these customers. Contingent consideration for the Bonus Amount will continue to be paid in arrears through the quarter ending December 31, 2025.  

The current contingent consideration for the Base Amount Plus and the Bonus Amount are recorded as a short-term liability on the balance sheet.  At March 31, 2023, the Base Amount, the Base Amount Plus and the Bonus Amount were recorded as intangible assets on the balance sheet with an estimated average useful life of 10 years.

18

Note 6.  Contingencies

COVID-19

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows.

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Inflation Risk

The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations for the three and nine months ended March 31, 2023 and 2022 should be read in conjunction with our consolidated financial statements and related notes to those financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements.

Overview

Research Solutions was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with three wholly owned subsidiaries at June 30, 2022: Reprints Desk, Inc., a Delaware corporation, Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

We provide two service offerings to our customers: a cloud-based software-as-a-service (“SaaS”) research platform (“Platforms”) typically sold via annual auto-renewing license agreements and the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via the Platform. When customers utilize the Platform to purchase Transactions it is packaged as a single solution that enables life science and other research intensive organizations to accelerate their research and development activities with faster, access and management of STM articles used throughout the intellectual property development lifecycle. The Platform typically delivers a ROI to the customer via more effectively managing Transaction costs and saving researchers time during the research process.

Platforms

Our cloud-based SaaS research Platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

Additional functionality has recently been added to our Platform in the form of interactive app-like components. An alternative to manual data filtering, identification and extraction, the apps are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We continue to develop new apps in order to build an ecosystem of apps. Together, these apps will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

20

Transactions

Our Platform provides our customers with a single source to the universe of published STM content that includes over 80 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour; in many cases under one minute. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

COVID-19

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of our financial statements, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.

Inflation Risk

We do not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that our operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing our operating costs, and which would put additional stress on our working capital resources.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions.

The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to an understanding of our financial statements because they inherently involve significant judgments and uncertainties.

21

Revenue Recognition

We account for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We derive our revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Stock-Based Compensation

The fair value of our stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted

22

stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Recent Accounting Pronouncements

Please refer to footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q for a discussion of Recent Accounting Pronouncements.

Quarterly Information (Unaudited)

The following table sets forth unaudited and quarterly financial data for the most recent eight quarters:

	Mar. 31,		Dec. 31,		Sept. 30,		June 30,		Mar. 31,		Dec 31,		Sept. 30,		June 30,
	2023		2022		2022		2022		2022		2021		2021		2021
Revenue:
Platforms	$	2,249,632	$	2,110,272	$	2,019,967	$	1,886,845	$	1,786,224	$	1,604,829	$	1,509,874	$	1,429,160
Transactions		8,092,794		6,606,394		6,664,676		6,675,164		6,971,128		6,267,458		6,232,630		6,788,494
Total revenue		10,342,426		8,716,666		8,684,643		8,562,009		8,757,352		7,872,287		7,742,504		8,217,654
Cost of revenue:
Platforms		268,630		253,073		230,473		240,214		219,051		231,668		245,656		257,320
Transactions		6,046,523		5,059,766		5,104,922		5,038,653		5,299,804		4,802,959		4,836,473		5,218,118
Total cost of revenue		6,315,153		5,312,839		5,335,395		5,278,867		5,518,855		5,034,627		5,082,129		5,475,438
Gross profit:
Platforms		1,981,022		1,857,199		1,789,494		1,646,631		1,567,173		1,373,161		1,264,218		1,171,840
Transactions		2,046,271		1,546,628		1,559,754		1,636,511		1,671,324		1,464,499		1,396,157		1,570,376
Total gross profit		4,027,273		3,403,827		3,349,248		3,283,142		3,238,497		2,837,660		2,660,375		2,742,216
Operating expenses:
Sales and marketing		642,624		666,608		521,216		691,368		543,496		518,357		522,951		521,220
Technology and product dev.		953,677		922,132		875,290		1,049,430		971,959		868,236		821,460		732,371
General and administrative		1,871,590		1,613,664		1,519,424		1,663,671		1,629,371		1,616,135		1,497,223		1,354,244
Depreciation and amortization		18,332		6,342		5,812		5,507		4,988		4,260		2,896		2,694
Stock-based comp. expense		480,458		608,703		175,361		225,501		399,234		300,539		171,110		221,589
Foreign currency transaction loss (gain)		(72,547)		(84,179)		72,516		91,279		29,394		11,982		11,243		(890)
Total operating expenses		3,894,134		3,733,270		3,169,619		3,726,756		3,578,442		3,319,509		3,026,883		2,831,228
Other income (expenses and income taxes)		103,703		73,913		34,936		5,347		(585)		264		(5,494)		136
Net income (loss)		236,842		(255,530)		214,565		(438,267)		(340,530)		(481,585)		(372,002)		(88,876)
Basic income (loss) per common share:
Net income (loss) per share	$	0.01	$	(0.01)	$	0.01	$	(0.02)	$	(0.01)	$	(0.02)	$	(0.01)	$	—
Basic weighted average common shares outstanding		26,929,314		26,816,550		26,718,171		26,576,054		26,512,195		26,351,947		26,277,116		26,145,794
Diluted income (loss) per common share:
Net income (loss) per share	$	0.01	$	(0.01)	$	0.01	$	(0.02)	$	(0.01)	$	(0.02)	$	(0.01)	$	—
Diluted weighted average common shares outstanding		29,791,719		26,815,550		27,779,841		26,576,054		26,512,195		26,351,947		26,277,116		26,145,794

23

Comparison of the Three and Nine Months Ended March 31, 2023 and 2022

Results of Operations

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	2,249,632	$	1,786,224	$	463,408	25.9	%
Transactions		8,092,794		6,971,128		1,121,666	16.1	%
Total revenue		10,342,426		8,757,352		1,585,074	18.1	%
Cost of revenue:
Platforms		268,630		219,051		49,579	22.6	%
Transactions		6,046,523		5,299,804		746,719	14.1	%
Total cost of revenue		6,315,153		5,518,855		796,298	14.4	%
Gross profit:
Platforms		1,981,002		1,567,173		413,829	26.4	%
Transactions		2,046,271		1,671,324		374,947	22.4	%
Total gross profit		4,027,273		3,238,497		788,776	24.4	%
Operating expenses:
Sales and marketing		642,624		543,496		99,128	18.2	%
Technology and product development		953,677		971,959		(18,282)	(1.9)	%
General and administrative		1,871,590		1,629,371		242,219	14.9	%
Depreciation and amortization		18,332		4,988		13,344	267.5	%
Stock-based compensation expense		480,458		399,234		81,224	20.3	%
Foreign currency transaction loss (gain)		(72,547)		29,394		(101,941)	(346.8)	%
Total operating expenses		3,894,134		3,578,442		315,692	8.8	%
Income (loss) from operations		133,139		(339,945)		473,084	139.2	%
Other income		104,331		237		104,094	43,921.5	%
Income (loss) from operations before provision for income taxes		237,470		(339,708)		577,178	169.9	%
Provision for income taxes		(628)		(822)		194	23.6	%
Net income (loss)	$	236,842	$	(340,530)		577,372	169.6	%

24

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	6,379,871	$	4,900,927	$	1,478,944	30.2	%
Transactions		21,363,864		19,471,216		1,892,648	9.7	%
Total revenue		27,743,735		24,372,143		3,371,592	13.8	%
Cost of revenue:
Platforms		752,176		696,375		55,801	8.0	%
Transactions		16,211,211		14,939,236		1,271,975	8.5	%
Total cost of revenue		16,963,387		15,635,611		1,327,776	8.5	%
Gross profit:
Platforms		5,627,695		4,204,552		1,423,143	33.8	%
Transactions		5,152,653		4,531,980		620,673	13.7	%
Total gross profit		10,780,348		8,736,532		2,043,816	23.4	%
Operating expenses:
Sales and marketing		1,830,448		1,584,804		245,644	15.5	%
Technology and product development		2,751,099		2,661,655		89,444	3.4	%
General and administrative		5,004,678		4,742,729		261,949	5.5	%
Depreciation and amortization		30,486		12,144		18,342	151.0	%
Stock-based compensation expense		1,264,522		870,883		393,639	45.2	%
Foreign currency transaction loss (gain)		(84,210)		52,619		(136,829)	(260.0)	%
Total operating expenses		10,797,023		9,924,834		872,189	8.8	%
Income (loss) from operations		(16,675)		(1,188,302)		1,171,627	98.6	%
Other income		218,095		777		217,318	27,968.9	%
Income (loss) from operations before provision for income taxes		201,420		(1,187,525)		1,388,945	117.0	%
Provision for income taxes		(5,543)		(6,592)		1,049	15.9	%
Net income (loss)	$	195,877	$	(1,194,117)	$	1,389,994	116.4	%

25

Revenue

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	2,249,632	$	1,786,224	$	463,408	25.9	%
Transactions		8,092,794		6,971,128		1,121,666	16.1	%
Total revenue	$	10,342,426	$	8,757,352	$	1,585,074	18.1	%

Total revenue increased $1,585,074, or 18.1%, for the three months ended March 31, 2023 compared to the prior year, due to the following:

Category	Impact			Key Drivers
Platforms	↑	$	436,408	Increased due to additional deployments to new and existing customers, and expansion from existing customers. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	1,121,666	Increased primarily due to higher paid order volume, including additional paid order volume due to the FIZ asset acquisition.

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Revenue:
Platforms	$	6,379,871	$	4,900,927	$	1,478,944	30.2	%
Transactions		21,363,864		19,471,216		1,892,648	9.7	%
Total revenue	$	27,743,735	$	24,372,143	$	3,371,592	13.8	%

Total revenue increased $3,371,592, or 13.8%, for the nine months ended March 31, 2023 compared to the prior year, due to the following:

Category	Impact			Key Drivers
Platforms	↑	$	1,478,944	Increased due to additional deployments to new and existing customers, and expansion from existing customers. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	1,892,648	Increased due to higher paid order volume and pricing initiatives, including additional paid order volume due to the FIZ asset acquisition.

Cost of Revenue

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Cost of Revenue:
Platforms	$	268,630	$	219,051	$	49,579	22.6	%
Transactions		6,046,523		5,299,804		746,719	14.1	%
Total cost of revenue	$	6,315,153	$	5,518,855	$	796,298	14.4	%

26

	Three Months Ended
	March 31,
	2023		2022		% Change *
As a percentage of revenue:
Platforms	11.9	%	12.3	%	(0.4)	%
Transactions	74.7	%	76.0	%	(1.3)	%
Total	61.1	%	63.0	%	(1.9)	%

* The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 1.9%, from 63% for the previous year to 61.1%, for the three months ended March 31, 2023.

	Impact as percentage
Category	of revenue			Key Drivers
Platforms	↓	0.4	%	Decreased primarily due to proportionally lower software expense and lower personnel costs.
Transactions	↓	1.3	%	Decreased primarily due to proportionally lower personnel costs.

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Cost of Revenue:
Platforms	$	752,176	$	696,375	$	55,801	8.0	%
Transactions		16,211,211		14,939,236		1,271,975	8.5	%
Total cost of revenue	$	16,963,387	$	15,635,611	$	1,327,776	8.5	%

	Nine Months Ended
	March 31,
	2023		2022		% Change *
As a percentage of revenue:
Platforms	11.8	%	14.2	%	(2.4)	%
Transactions	75.9	%	76.7	%	(0.8)	%
Total	61.1	%	64.2	%	(3.1)	%

* The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 3.1%, from 64.2% for the previous year to 61.1%, for the nine months ended March 31, 2023.

	Impact as percentage
Category	of revenue			Key Drivers
Platforms	↓	2.4	%	Decreased primarily due to lower software expense and proportionally lower personnel costs.
Transactions	↓	0.8	%	Decreased primarily due to proportionally lower personnel costs.

27

Gross Profit

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Gross Profit:
Platforms	$	1,981,002	$	1,567,173	$	413,829	26.4	%
Transactions		2,046,271		1,671,324		374,947	22.4	%
Total gross profit	$	4,027,273	$	3,238,497	$	788,776	24.4	%

	Three Months Ended
	March 31,
	2023		2022		% Change*
As a percentage of revenue:
Platforms	88.1	%	87.7	%	0.4	%
Transactions	25.3	%	24.0	%	1.3	%
Total	38.9	%	37.0	%	1.9	%

* The difference between current and prior period gross profit as a percentage of revenue

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Gross Profit:
Platforms	$	5,627,695	$	4,204,552	$	1,423,143	33.8	%
Transactions		5,152,653		4,531,980		620,673	13.7	%
Total gross profit	$	10,780,348	$	8,736,532	$	2,043,816	23.4	%

	Nine Months Ended
	March 31,
	2023		2022		% Change*
As a percentage of revenue:
Platforms	88.2	%	85.8	%	2.4	%
Transactions	24.1	%	23.3	%	0.8	%
Total	38.9	%	35.8	%	3.1	%

* The difference between current and prior period gross profit as a percentage of revenue

Operating Expenses

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Operating Expenses:
Sales and marketing	$	642,624	$	543,496	$	99,128	18.2	%
Technology and product development		953,677		971,959		(18,282)	(1.9)	%
General and administrative		1,871,590		1,629,371		242,219	14.9	%
Depreciation and amortization		18,332		4,988		13,344	267.5	%
Stock-based compensation expense		480,458		399,234		81,224	20.3	%
Foreign currency transaction loss		(72,547)		29,394		(101,941)	(346.8)	%
Total operating expenses	$	3,894,134	$	3,578,442	$	315,692	8.8	%

28

Category	Impact			Key Drivers
Sales and marketing	↑	$	99,128	Increased primarily due to greater personnel costs and marketing discretionary spend partially offset by lower consulting expenses.
Technology and product development	↓	$	(18,282)	Decreased due to lower consulting and recruiting expenses partially offset by greater software development personnel costs.
General and administrative	↑	$	242,219	Increased due to greater recruiting expenses and personnel costs partially offset by lower accounting, legal and consulting expenses.

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Operating Expenses:
Sales and marketing	$	1,830,448	$	1,584,804	$	245,644	15.5	%
Technology and product development		2,751,099		2,661,655		89,444	3.4	%
General and administrative		5,004,678		4,742,729		261,949	5.5	%
Depreciation and amortization		30,486		12,144		18,342	151.0	%
Stock-based compensation expense		1,264,522		870,883		393,639	45.2	%
Foreign currency transaction loss		(84,210)		52,619		(136,829)	(260.0)	%
Total operating expenses	$	10,797,023	$	9,924,834	$	872,189	8.8	%

Category	Impact			Key Drivers
Sales and marketing	↑	$	245,644	Increased primarily due to greater personnel costs and marketing discretionary spend partially offset by lower consulting expenses.
Technology and product development	↑	$	89,444	Increased due to greater software development personnel costs partially offset by lower consulting and recruiting expenses.
General and administrative	↑	$	261,949	Increased due to greater recruiting expenses and personnel costs partially offset by lower accounting, legal and consulting expenses.

Net Income (Loss)

	Three Months Ended March 31,
	2023		2022		$ Change		% Change
Net Income (Loss):
Net income (loss):	$	236,842	$	(340,530)	$	577,372	169.6	%

Net loss decreased $577,372 or 169.6%, for the three months ended March 31, 2023 compared to the prior year, primarily due to increased gross profit, partially offset by increased operating expenses as described above.

	Nine Months Ended March 31,
	2023		2022		$ Change		% Change
Net Income (Loss):
Net income (loss):	$	195,877	$	(1,194,117)	$	1,389,994	116.4	%

Net loss decreased $1,389,994 or 116.4%, for the nine months ended March 31, 2023 compared to the prior year, primarily due to increased gross profit, partially offset by increased operating expenses as described above.

29

Liquidity and Capital Resources

	Nine Months Ended March 31,
	2023		2022
Consolidated Statements of Cash Flow Data:
Net cash provided by (used in) operating activities	$	1,872,356	$	(402,711)
Net cash used in investing activities		(327,426)		(34,251)
Net cash provided by (used in) financing activities		(17,056)		75,135
Effect of exchange rate changes		1,850		(1,989)
Net increase (decrease) in cash and cash equivalents		1,529,724		(363,816)
Cash and cash equivalents, beginning of period		10,603,175		11,004,337
Cash and cash equivalents, end of period	$	12,132,899	$	10,640,521

Liquidity

As of March 31, 2023, we had cash and cash equivalents of $12,132,899, compared to $10,603,175 as of June 30, 2022, an increase of $1,529,724. This increase was primarily due to cash provided by operating activities.

Operating Activities

Net cash provided by operating activities was $1,872,356 for the nine months ended March 31, 2023 and resulted primarily from an increase in deferred revenue of $986,044, an increase in accounts payable and accrued expenses of $947,789 and an increase in fair value of vested restricted common stock of $925,550, partially offset by an increase in accounts receivable of $1,545,695.

Net cash used in operating activities was $402,711 for the nine months ended March 31, 2022 and resulted primarily from an increase in accounts receivable of $904,915, partially offset by an increase in deferred revenue of $538,477 and an increase in accounts payable and accrued expenses of $397,088.

Investing Activities

Net cash used in investing activities was $327,426 for the nine months ended March 31, 2023 and resulted primarily from the payment for non-refundable deposit for asset acquisition of $297,450.

Net cash used in investing activities was $34,251 for the nine months ended March 31, 2022 and resulted from the purchase of property and equipment.

Financing Activities

Net cash used in financing activities was $17,056 for the nine months ended March 31, 2023 and resulted from the repurchase of common stock of $74,556, partially offset by the proceeds from the exercise of options of $57,500.

Net cash provided by financing activities was $75,135 for the nine months ended March 31, 2022 and resulted from the proceeds from the exercise of options of $97,688 and the proceeds from the exercise of warrants of $59,500, partially offset by the repurchase of common stock of $82,053.

We entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 28, 2024, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2023. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and 5.0%. The interest rate on the line of credit was 9% as of March 31, 2023. The line of credit was secured by our consolidated assets.

30

There were no outstanding borrowings under the line as of March 31, 2023 and June 30, 2022, respectively. As of March 31, 2023, there was approximately $2,500,000 of available credit. On March 27, 2023, First Citizens BancShares, Inc entered into an agreement with the Federal Deposit Insurance Corporation (FDIC) to purchase all of the assets and liabilities of SVB. We have confirmed that the Loan and Security Agreement remains in effect post this transaction and that, in addition to having access to all of our deposits with SVB, we continue to have access to the revolving line of credit.

On March 28, 2023, we announced that we are continuing to evaluate the Loan and Security Agreement and relationship with SVB and that we have opened accounts with two additional banks as part of exploring an overall banking diversification strategy as well as additional access to lending facilities.

Non-GAAP Measure – Adjusted EBITDA

In addition to our GAAP results, we present Adjusted EBITDA as a supplemental measure of our performance. However, Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of liquidity. We define Adjusted EBITDA as net income (loss), plus interest expense, other income (expense), foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, income from discontinued operations and gain on sale of discontinued operations. Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three and nine months ended March 31, 2023 and 2022:

	Three Months Ended
	March 31,
	2023		2022		$ Change
Net income (loss)	$	236,842	$	(340,530)	$	577,372
Add (deduct):
Other (income) expense		(104,331)		(237)		(104,094)
Foreign currency transaction loss (gain)		(72,547)		29,394		(101,941)
Provision for income taxes		628		822		(194)
Depreciation and amortization		18,332		4,988		13,344
Stock-based compensation		480,458		399,234		81,224
Adjusted EBITDA	$	559,382	$	93,671	$	465,711

	Nine Months Ended
	March 31,
	2023		2022		$ Change
Net income (loss)	$	195,877	$	(1,194,117)	$	1,389,994
Add (deduct):
Other (income) expense		(218,095)		(777)		(217,318)
Foreign currency transaction loss (gain)		(84,210)		52,619		(136,829)
Provision for income taxes		5,543		6,592		(1,049)
Depreciation and amortization		30,486		12,144		18,342
Stock-based compensation		1,264,522		870,883		393,639
Adjusted EBITDA	$	1,194,123	$	(252,656)	$	1,446,779

We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating

31

performance. In addition, we use Adjusted EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; and in making compensation decisions and in communications with our board of directors concerning our financial performance. Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following:

● Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

● Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

● Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and

● Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2023, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.

Inherent Limitations on the Effectiveness of Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

32

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control Over Financial Reporting

In addition, our management with the participation of our principal executive officer and principal financial officer have determined that no change in our internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Exchange Act) occurred during the quarter ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1A. Risk Factors.

The COVID-19 pandemic may reduce the number of articles ordered by our transactional customers, or may reduce the number of platform subscriptions, either of which could have a material adverse impact on our business and financial performance.

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows. However, the COVID-19 pandemic’s continued impact on the economy and our customers may reduce the number of articles ordered by our transactional customers, or may reduce the number of platform subscriptions, either of which could have a material adverse impact on our business and financial performance.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of our financial statements for the fiscal quarter ended March 31, 2023, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Effective as of February 9, 2021, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2021 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The Compensation Committee of our Board of Directors subsequently approved the extension of the repurchases under the same terms through the end of fiscal year 2023. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. As of June 30, 2022, $255,345 remained under the current authorization to repurchase our outstanding common stock from our employees.

33

During the three months ended March 31, 2023, we repurchased 12,785 shares of our common stock from employees at an average market price of approximately $2.02 per share for an aggregate amount of $25,827. As of March 31, 2023, $180,790 remains under the current authorization to repurchase our outstanding common stock from our employees.

Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

The following table summarizes repurchases of our common stock on a monthly basis:

				Total Number of Shares	Approximate Dollar Value
	Total Number	Average		Purchased as Part of	of Shares that May Yet Be
	of Shares	Price Paid		Publicly Announced	Purchased Under the
Period	Purchased1	per Share		Plans or Programs	Plans or Programs
January 1-31, 2023	—		—	—	$	206,616
February 1-28, 2023	—		—	—	$	206,616
March 1-31, 2023	12,785	$	2.02	—	$	180,789
Total	12,785	$	2.02	—		—

¹ Consists of shares of common stock purchased from an employee to satisfy tax obligations in connection with the vesting of stock incentive awards.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit Number	Description
3.1.1	Articles of Incorporation. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form SB-2 filed on December 28, 2007.)
3.1.2	Articles of Merger Effective March 4, 2013. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on March 6, 2013.)
3.2	Amended and Restated Bylaws. (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on October 17, 2012.)
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer *
32.2	Section 1350 Certification of Chief Financial Officer *
101.INS	INLINE XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

*      Furnished herewith

34

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	RESEARCH SOLUTIONS, INC.
	By:	/s/ Roy W. Olivier
		Roy W. Olivier
Date: May 12, 2023		Chief Executive Officer and President (Principal Executive Officer)
	By:	/s/ William Nurthen
		William Nurthen
Date: May 12, 2023		Chief Financial Officer (Principal Financial and Accounting Officer)

35

EX-31.1

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION

I, Roy W. Olivier, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:     May 12, 2023	/s/ Roy W. Olivier
	Roy W. Olivier
	Chief Executive Officer and President (Principal Executive Officer)

EX-31.2

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION

I, William Nurthen, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:      May 12, 2023	/s/ William Nurthen
	William Nurthen
	Chief Financial Officer (Principal Financial and
	Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roy W. Olivier, Chief Executive Officer and President, and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Roy W. Olivier

Roy W. Olivier

Chief Executive Officer and President

(Principal Executive Officer)

May 12, 2023

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William Nurthen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ William Nurthen

William Nurthen

Chief Financial Officer (Principal Financial and Accounting Officer)

May 12, 2023

XML

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2023	May 05, 2023
Document And Entity Information
Document Type	10-Q
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-39256
Entity Registrant Name	RESEARCH SOLUTIONS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	11-3797644
Entity Address, Address Line One	Address not applicable1
Entity Address, City or Town	N/A
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	N/A
City Area Code	310
Local Phone Number	477-0354
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	RSSS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,500,764
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001386301
Amendment Flag	false
Document Quarterly Report	true

XML

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 12,132,899	$ 10,603,175
Accounts receivable, net of allowance of $49,670 and $94,144, respectively	6,797,240	5,251,545
Prepaid expenses and other current assets	398,726	276,026
Prepaid royalties	798,892	846,652
Total current assets	20,127,757	16,977,398
Other assets:
Property and equipment, net of accumulated depreciation of $868,324 and $840,996, respectively	53,766	47,985
Intangible assets, net of accumulated amortization of $11,046 and $0, respectively	430,788	0
Deposits and other assets	997	893
Total assets	20,613,308	17,026,276
Current liabilities:
Accounts payable and accrued expenses	7,696,205	6,604,032
Deferred revenue	6,524,570	5,538,526
Total current liabilities	14,220,775	12,142,558
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 29,500,764 and 27,075,648 shares issued and outstanding, respectively	29,501	27,076
Additional paid-in capital	29,386,169	28,072,855
Accumulated deficit	(22,898,395)	(23,094,272)
Accumulated other comprehensive loss	(124,742)	(121,941)
Total stockholders' equity	6,392,533	4,883,718
Total liabilities and stockholders' equity	$ 20,613,308	$ 17,026,276

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Condensed Consolidated Balance Sheets
Allowance for doubtful accounts	$ 49,670	$ 94,144
Accumulated depreciation property and equipment	868,324	840,996
Intangible assets, accumulated amortization	$ 11,046	$ 0
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	29,500,764	27,075,648
Common Stock, Shares, Outstanding	29,500,764	27,075,648

XML

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 10,342,426	$ 8,757,352	$ 27,743,735	$ 24,372,143
Cost of revenue:
Total cost of revenue	6,315,153	5,518,855	16,963,387	15,635,611
Gross profit	4,027,273	3,238,497	10,780,348	8,736,532
Operating expenses:
Selling, general and administrative	3,875,802	3,573,454	10,766,537	9,912,690
Depreciation and amortization	18,332	4,988	30,486	12,144
Total operating expenses	3,894,134	3,578,442	10,797,023	9,924,834
Income (loss) from operations	133,139	(339,945)	(16,675)	(1,188,302)
Other income	104,331	237	218,095	777
Income (loss) from operations before provision for income taxes	237,470	(339,708)	201,420	(1,187,525)
Provision for income taxes	(628)	(822)	(5,543)	(6,592)
Net income (loss)	236,842	(340,530)	195,877	(1,194,117)
Other comprehensive income (loss):
Foreign currency translation	(4,149)	1,609	(2,801)	(1,181)
Comprehensive income (loss)	$ 232,693	$ (338,921)	$ 193,076	$ (1,195,298)
Income (loss) per common share:
Net loss per share, basic	$ 0.01	$ (0.01)	$ 0.01	$ (0.05)
Net loss per share, diluted	$ 0.01	$ (0.01)	$ 0.01	$ (0.05)
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic	26,929,314	26,512,195	26,820,557	26,392,949
Weighted average common shares outstanding, diluted	29,791,719	26,512,195	28,837,774	26,392,949
Platforms
Revenue:
Total revenue	$ 2,249,632	$ 1,786,224	$ 6,379,871	$ 4,900,927
Cost of revenue:
Total cost of revenue	268,630	219,051	752,176	696,375
Transactions
Revenue:
Total revenue	8,092,794	6,971,128	21,363,864	19,471,216
Cost of revenue:
Total cost of revenue	$ 6,046,523	$ 5,299,804	$ 16,211,211	$ 14,939,236

XML

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Total
Balance at Jun. 30, 2021	$ 26,498	$ 26,982,052	$ (21,461,888)	$ (119,577)	$ 5,427,085
Balance (in shares) at Jun. 30, 2021	26,498,215
Fair value of vested stock options		424,450			424,450
Fair value of vested restricted common stock	$ 293	446,140			446,433
Fair value of vested restricted common stock (in shares)	293,211
Repurchase of common stock	$ (34)	(82,019)			(82,053)
Repurchase of common stock (in shares)	(33,402)
Common stock issued upon exercise of stock options	$ 194	97,494			97,688
Common stock issued upon exercise of stock options (in shares)	192,820
Common stock issued upon exercise of warrants	$ 50	59,450			59,500
Common stock issued upon exercise of warrants (in shares)	50,000
Net income (loss) for the period			(1,194,117)		(1,194,117)
Foreign currency translation				(1,181)	(1,181)
Balance at Mar. 31, 2022	$ 27,001	27,927,567	(22,656,005)	(120,758)	5,177,805
Balance (in shares) at Mar. 31, 2022	27,000,844
Balance at Jun. 30, 2021	$ 26,498	26,982,052	(21,461,888)	(119,577)	5,427,085
Balance (in shares) at Jun. 30, 2021	26,498,215
Balance at Jun. 30, 2022	$ 27,076	28,072,855	(23,094,272)	(121,941)	4,883,718
Balance (in shares) at Jun. 30, 2022	27,075,648
Balance at Dec. 31, 2021	$ 26,817	27,475,741	(22,315,475)	(122,367)	5,064,716
Balance (in shares) at Dec. 31, 2021	26,817,056
Fair value of vested stock options		296,782			296,782
Fair value of vested restricted common stock	$ 42	102,410			102,452
Fair value of vested restricted common stock (in shares)	42,214
Repurchase of common stock	$ (6)	(14,235)			(14,241)
Repurchase of common stock (in shares)	(6,086)
Common stock issued upon exercise of stock options	$ 148	66,869			67,017
Common stock issued upon exercise of stock options (in shares)	147,660
Net income (loss) for the period			(340,530)		(340,530)
Foreign currency translation				1,609	1,609
Balance at Mar. 31, 2022	$ 27,001	27,927,567	(22,656,005)	(120,758)	5,177,805
Balance (in shares) at Mar. 31, 2022	27,000,844
Balance at Jun. 30, 2022	$ 27,076	28,072,855	(23,094,272)	(121,941)	4,883,718
Balance (in shares) at Jun. 30, 2022	27,075,648
Fair value of vested stock options		338,973			338,973
Fair value of vested restricted common stock	$ 2,355	923,195			925,550
Fair value of vested restricted common stock (in shares)	2,354,834
Fair value of vested unrestricted common stock	$ 36	68,236			68,272
Fair value of vested unrestricted common stock (in shares)	36,509
Repurchase of common stock	$ (38)	(74,518)			(74,556)
Repurchase of common stock (in shares)	(38,585)
Forfeited restricted common stock	$ (65)	65
Forfeited restricted common stock (in shares)	(65,165)
Common stock issued upon exercise of stock options	$ 137	57,363			$ 57,500
Common stock issued upon exercise of stock options (in shares)	137,523				307,298
Net income (loss) for the period			195,877		$ 195,877
Foreign currency translation				(2,801)	(2,801)
Balance at Mar. 31, 2023	$ 29,501	29,386,169	(22,898,395)	(124,742)	6,392,533
Balance (in shares) at Mar. 31, 2023	29,500,764
Balance at Dec. 31, 2022	$ 29,155	28,874,383	(23,135,237)	(120,593)	5,647,708
Balance (in shares) at Dec. 31, 2022	29,154,737
Fair value of vested stock options		37,236			37,236
Fair value of vested restricted common stock	$ 333	442,890			443,223
Fair value of vested restricted common stock (in shares)	332,500
Repurchase of common stock	$ (13)	(25,814)			(25,827)
Repurchase of common stock (in shares)	(12,785)
Forfeited restricted common stock	$ (65)	65
Forfeited restricted common stock (in shares)	(65,165)
Common stock issued upon exercise of stock options	$ 91	57,409			57,500
Common stock issued upon exercise of stock options (in shares)	91,477
Net income (loss) for the period			236,842		236,842
Foreign currency translation				(4,149)	(4,149)
Balance at Mar. 31, 2023	$ 29,501	$ 29,386,169	$ (22,898,395)	$ (124,742)	$ 6,392,533
Balance (in shares) at Mar. 31, 2023	29,500,764

XML

Condensed Consolidated Statements of Cash Flows	9 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Cash flow from operating activities:
Net income (loss)	$ 195,877	$ (1,194,117)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	30,486	12,144
Fair value of vested stock options	338,973	424,450
Fair value of vested restricted common stock	925,550	446,433
Fair value of vested unrestricted common stock	68,272	0
Changes in operating assets and liabilities:
Accounts receivable	(1,545,695)	(904,915)
Prepaid expenses and other current assets	(122,700)	(67,984)
Prepaid royalties	47,760	(54,287)
Accounts payable and accrued expenses	947,789	397,088
Deferred revenue	986,044	538,477
Net cash provided by (used in) operating activities	1,872,356	(402,711)
Cash flow from investing activities:
Purchase of property and equipment	(29,976)	(34,251)
Payment for non-refundable deposit for asset acquisition	(297,450)	0
Net cash used in investing activities	(327,426)	(34,251)
Cash flow from financing activities:
Proceeds from the exercise of stock options	57,500	97,688
Proceeds from the exercise of warrants	0	59,500
Common stock repurchase	(74,556)	(82,053)
Net cash provided by (used in) financing activities	(17,056)	75,135
Effect of exchange rate changes	1,850	(1,989)
Net increase (decrease) in cash and cash equivalents	1,529,724	(363,816)
Cash and cash equivalents, beginning of period	10,603,175	11,004,337
Cash and cash equivalents, end of period	12,132,899	10,640,521
Supplemental disclosures of cash flow information:
Cash paid for income taxes	5,543	6,592
Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$ 144,384	$ 0

XML

Organization, Nature of Business and Basis of Presentation

9 Months Ended

Mar. 31, 2023

Organization, Nature of Business and Basis of Presentation

Organization, Nature of Business and Basis of Presentation

Note 1.  Organization, Nature of Business and Basis of Presentation

Organization

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with three wholly owned subsidiaries: Reprints Desk, Inc., (“Reprints Desk”) a Delaware corporation, Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Nature of Business

We provide two service offerings to our customers: a cloud-based software-as-a-service (“SaaS”) research platform (“Platforms”) typically sold via annual auto-renewing license agreements and the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via the Platform. When customers utilize the Platform to purchase Transactions it is packaged as a single solution that enables life science and other research intensive organizations to accelerate their research and development activities with faster, access and management of STM articles used throughout the intellectual property development lifecycle. The Platform typically delivers a ROI to the customer via more effectively managing Transaction costs and saving researchers time during the research process.

Platforms

Our cloud-based SaaS research Platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

Additional functionality has recently been added to our Platform in the form of interactive app-like components. An alternative to manual data filtering, identification and extraction, the apps are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We continue to develop new apps in order to build an ecosystem of apps. Together, these apps will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

Transactions

Our Platform provides our customers with a single source to the universe of published STM content that includes over 80 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour; in many cases under one minute. This service is generally known in the industry

as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

Principles of Consolidation

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2022 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

XML

Summary of Significant Accounting Policies

9 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2.   Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, impairment related to intangible assets and realization of deferred tax assets.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2023 and June 30, 2022.

The following table summarizes vendor concentrations:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Vendor A	23	%	22	%	22	%	21	%
Vendor B	14	%	13	%	13	%	13	%

Revenue Recognition

The Company accounts for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Revenue by Geographical Region

The following table summarizes revenue by geographical region:

	Three Months Ended
	March 31,
	2023				2022
United States	$	5,892,424	57.0	%	$	5,027,965	57.4	%
Europe		3,530,469	34.1	%		3,159,984	36.1	%
Rest of World		919,533	8.9	%		569,403	6.5	%
Total	$	10,342,426	100	%	$	8,757,352	100	%

	Nine Months Ended
	March 31,
	2023				2022
United States	$	15,997,407	57.7	%	$	14,222,605	58.4	%
Europe		9,503,235	34.3	%		8,488,722	34.8	%
Rest of World		2,243,093	8.1	%		1,660,816	6.8	%
Total	$	27,743,735	100	%	$	24,372,143	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:

	As of March 31, 2023				As of June 30, 2022
United States	$	4,041,180	59.5	%	$	3,255,976	62.0	%
Europe		2,020,602	29.7	%		1,665,111	31.7	%
Rest of World		735,458	10.8	%		330,458	6.3	%
Total	$	6,797,240	100	%	$	5,251,545	100	%

Deferred Revenue

Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer.

Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

Foreign Currency

The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gain of $72,547 and $84,210 for the three and nine months ended March 31, 2023, respectively and losses of $29,394 and $52,619 for the three and nine months ended March 31, 2022, respectively. Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held in accounts at financial institutions located in Europe.

The following table summarizes the exchange rates used:

	Nine Months Ended		Year Ended
	March 31,		June 30,
	2023	2022	2023	2021
Period end Euro : US Dollar exchange rate	1.09	1.11	1.05	1.19
Average period Euro : US Dollar exchange rate	1.03	1.15	1.13	1.19
Period end GBP : US Dollar exchange rate	1.24	1.31	1.21	1.38
Average period GBP : US Dollar exchange rate	1.19	1.36	1.34	1.34
Period end Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05
Average period Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted

earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2023 potentially dilutive securities include options to acquire 2,925,574 shares of common stock and unvested restricted common stock of 2,528,187. At March 31, 2022 potentially dilutive securities include options to acquire 3,249,617 shares of common stock and unvested restricted common stock of 364,675. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2022 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three and nine months ended March 31, 2023, the calculation of diluted earnings per share include unvested restricted common stock, stock options and warrants, calculated under the treasury stock method.  

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

XML

Line of Credit

9 Months Ended

Mar. 31, 2023

Line of Credit

Line of Credit

Note 3.   Line of Credit

The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 28, 2024, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2023. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and 5.0%. The interest rate on the line of credit was 9% as of March 31, 2023. The line of credit is secured by the Company’s consolidated assets.

Pursuant to the Amended and Restated Loan and Security Agreement dated October 31, 2017 among the Company, Reprints Desk, Inc. and SVB (the “SVB LSA”), the Company was required to direct account debtors to deliver or transmit all proceeds of accounts remitted to the Company and its subsidiaries into a lockbox account as specified by SVB, and to maintain its and its subsidiaries’ primary operating and other deposit accounts with SVB.  In compliance with the foregoing covenants the Company and its subsidiaries maintained with SVB substantially all of the dollar value of the Company’s and its subsidiaries’ accounts. At February 28, 2023, the Company held cash at SVB of $10,832,880, of which we estimate $9,738,292 was in excess of government insured limits.    

On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank, N.A. (“SVB Bridge Bank”). On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors’ insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 14, 2023, the Company was able to access its full deposits with SVB Bridge Bank. At March 31, 2023, the

Company held cash at SVB Bridge Bank of $10,474,449, of which we estimate $9,406,136 was in excess of government insured limits.

There were no outstanding borrowings under the line as of March 31, 2023 and June 30, 2022, respectively. As of March 31, 2023, there was approximately $2,500,000 of available credit.

SVB Bridge Bank agreed that the Company can lower its cash balance threshold requirement associated with the SVB LSA, reducing the required balances of its and its subsidiaries’ primary operating and other accounts with SVB, and the Company continues to evaluate the SVB LSA. At March 31, 2023, the Company also held cash at Bank of America, N.A. of $750,000 and at PNC Bank, N.A. of $905,510. The Company continues to re-allocate its cash position across all three banks and explore an overall banking diversification strategy as well as additional access to lending facilities.

XML

Stockholders' Equity

9 Months Ended

Mar. 31, 2023

Stockholders' Equity

Stockholders' Equity

Note 4.   Stockholders’ Equity

Stock Options

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 17, 2020, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 2,374,513 to 3,374,513. On November 17, 2021, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 3,374,513 to 6,874,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of March 31, 2023, there were 1,495,927 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

The following table summarizes vested and unvested stock option activity:

	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2022	3,182,872	$	1.79	2,999,974	$	1.75	182,898	$	2.49
Granted	200,000		2.15	—		—	200,000		2.15
Options vesting	—		—	309,486		2.27	(309,486)		2.27
Exercised	(307,298)		1.31	(307,298)		1.31	—		—
Forfeited	(150,000)		1.81	(147,917)		1.78	(2,083)		3.92
Repurchased	—		—	—		—	—		—
Outstanding at March 31, 2023	2,925,574	$	1.87	2,854,245	$	1.85	71,329	$	2.46

The weighted average remaining contractual life of all options outstanding as of March 31, 2023 was 5.71 years. The remaining contractual life for options vested and exercisable at March 31, 2023 was 5.65 years. Furthermore, the aggregate intrinsic value of options outstanding and of options vested and exercisable as of March 31, 2023 was $1,060,516, in each case based on the fair value of the Company’s common stock on March 31, 2023.

During the nine months ended March 31, 2023, the Company granted 200,000 options to directors with a fair value of $222,000 which, due to immediate vesting, were fully expensed at the time of grant. The total fair value of options that vested during the nine months ended March 31, 2023 was $338,973 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of March 31, 2023, the amount of unvested compensation related to stock options was $92,793 which will be recorded as an expense in future periods as the options vest. During the nine months ended March 31, 2023, the Company issued 137,523 net shares of common stock upon the exercise of options underlying 307,298 shares of common stock, resulting in net cash proceeds of $57,500.

The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2023 and 2022.

	Nine Months Ended
	March 31,
	2023		2022
Expected dividend yield	—	%	—	%
Risk-free interest rate	3.76	%	0.92 - 1.81	%
Expected life (in years)	5		5 - 6
Expected volatility	56	%	56	%

Additional information regarding stock options outstanding and exercisable as of March 31, 2023 is as follows:

	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	2.68	225,000
	0.77	25,000	1.39	25,000
	0.80	16,000	2.39	16,000
	0.90	15,000	2.35	15,000
	1.00	15,000	1.95	15,000
	1.05	305,000	3.40	305,000
	1.09	40,000	3.15	40,000
	1.10	105,000	2.25	105,000
	1.20	274,000	4.30	274,000
	1.59	25,000	5.12	25,000
	1.80	54,550	0.48	54,550
	1.85	16,000	0.14	16,000
	1.95	200,000	5.26	200,000
	2.10	238,767	8.87	238,767
	2.13	216,708	7.64	213,922
	2.15	200,000	9.70	200,000
	2.17	35,955	8.12	23,970
	2.19	5,000	8.81	2,083
	2.40	302,833	5.63	302,833
	2.43	61,250	8.18	51,250
	2.45	163,000	7.35	149,416
	2.49	78,435	7.17	75,076
	2.50	20,000	6.13	20,000
	2.64	30,882	8.35	18,015
	2.67	33,194	8.47	19,363
	2.99	8,000	7.12	8,000
	3.13	208,000	6.62	208,000
	3.50	8,000	6.87	8,000
	Total	2,925,574		2,854,245

Restricted Common Stock

Prior to July 1, 2022, the Company issued 2,829,758 shares of restricted common stock to employees valued at $4,024,308, of which 2,215,342 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $3,060,652 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 400,092 at June 30, 2022, with an aggregate fair value of $775,453.

During the nine months ended March 31, 2023, the Company issued an additional 2,354,834 shares of restricted stock to employees with an aggregate fair value of $3,478,878. Of this amount, 229,834 shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met and 25,000 shares vest over a four year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of these stock awards was $503,478 based on the market price of our common stock price ranging from $1.94 to $2.22 per share on the date of grant, which will be amortized over the range of three and four-year vesting periods. The remaining 2,100,000 shares were granted, under the 2017 Plan, as restricted stock awards to key management in accordance with its long-term equity bonus program (the “LTEBP”). The LTEBP replaces the previous restricted stock compensation program for executives. It spans 5 years and is designed to better serve stockholder interests by aligning key executive compensation with stockholder value.  Awards under the LTEBP will vest as follows, upon the 30-day volume weighted average price (VWAP) of our common stock reaching the following targets:

•20% at a 30-day VWAP of $3.00 per share;

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

Upon a change of control vesting will accelerate with respect to that portion of the award that would vest if the target 30-day VWAP was achieved at the level above the per share price in such change of control transaction. For example, if we granted an award of 100,000 shares under the LTEBP, 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.00 per share, and 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.75 per share. If the per share price in a change of control transaction was $5.00 per share, vesting would accelerate for 40,000 shares under the same award (i.e. the number of shares that would vest for our stock price achieving a 30-day VWAP of $5.25 per share, pursuant to a tier round up provision in the Plan effective upon a change in control). As a condition to receiving awards under the LTEBP, recipients will be required to hold at least 75% of all vested shares during the term of their employment. Applicable target 30-day VWAPs must be achieved within 5 years following the grant of awards under the LTEBP, and all unvested awards under the LTEBP will be forfeited upon expiration of such 5-year period. Recipients will also forfeit unvested awards in the event their service with our company terminates for any reason.

As the vesting of the 2,100,000 shares of restricted common stock under the LTEBP is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value to be $2,975,400, computed using the Monte Carlo simulations on a binomial model with the assistance of a valuation specialist with a derived service period ranging from 1.36 to 2.59 years. The total fair value of restricted common stock vesting and expenses related to amortization of the fair value of the LTEBP program during the nine months ended March 31, 2023 was $925,549 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of March 31, 2023, the amount of unvested compensation related to issuances of restricted common stock was $3,204,829, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. When calculating net loss per share, the 2,528,187 shares are considered antidilutive and are excluded from that calculation.

The following table summarizes restricted common stock activity:

				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2022	400,092	$	775,453	$	2.38
Granted	2,354,834		3,478,878		1.48
Vested	(161,574)		(925,549)		2.49
Forfeited	(65,165)		(123,953)		2.15
Non-vested, March 31, 2023	2,528,187	$	3,204,829	$	1.54

Common Stock Repurchases

Effective as of February 9, 2021, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2021 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The Compensation Committee of our Board of Directors subsequently approved the extension of the repurchases under the same terms through the end of fiscal year 2023. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. As of June 30, 2022, $255,345 remained under the current authorization to repurchase our outstanding common stock from our employees.

During the nine months ended March 31, 2023, the Company repurchased 38,585 shares of our common stock from employees at an average market price of approximately $1.93 per share for an aggregate amount of $74,556. As of March 31, 2023, $180,789 remains under the current authorization to repurchase our outstanding common stock from our employees.

Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

XML

Acquisition

9 Months Ended

Mar. 31, 2023

Acquisition

Acquisition

Note 5.  Acquisition

On September 28, 2022, Reprints Desk entered into an asset purchase agreement with FIZ Karlsruhe – Leibniz-Institut für Informationsinfrastruktur GmbH (“FIZ”). FIZ delivers STM content pursuant to various contracts with its customers through its AutoDoc platform. FIZ has agreed to assign and transfer to Reprints Desk certain of these contracts effective January 1, 2023 (the “Sold Contracts”).  

On September 30, 2022, Reprints Desk made a non-refundable payment of $297,450 (€300,000) (the “Base Amount”) as initial consideration for the asset purchase. On March 31, 2023, Reprints Desk recorded $95,689 in contingent consideration for customers that have their Sold Contracts assumed by Reprints Desk in comparison to the trailing twelve months of revenue of all Sold Contracts (the “Base Amount Plus”). On March 31, 2023, $48,695 in contingent consideration was recorded for customers that placed an order and have consented to have their contract assumed by Reprints Desk (the “Bonus Amount”). The Bonus Amount is based upon the collectable service fee that FIZ would have received from these customers. Contingent consideration for the Bonus Amount will continue to be paid in arrears through the quarter ending December 31, 2025.  

The current contingent consideration for the Base Amount Plus and the Bonus Amount are recorded as a short-term liability on the balance sheet.  At March 31, 2023, the Base Amount, the Base Amount Plus and the Bonus Amount were recorded as intangible assets on the balance sheet with an estimated average useful life of 10 years.

XML

Contingencies

9 Months Ended

Mar. 31, 2023

Contingencies

Contingencies

Note 6.  Contingencies

COVID-19

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows.

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Inflation Risk

The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, impairment related to intangible assets and realization of deferred tax assets.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2023 and 2022.

The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2023 and June 30, 2022.

The following table summarizes vendor concentrations:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Vendor A	23	%	22	%	22	%	21	%
Vendor B	14	%	13	%	13	%	13	%

Revenue Recognition

Revenue Recognition

The Company accounts for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Revenue by Geographical Region

The following table summarizes revenue by geographical region:

	Three Months Ended
	March 31,
	2023				2022
United States	$	5,892,424	57.0	%	$	5,027,965	57.4	%
Europe		3,530,469	34.1	%		3,159,984	36.1	%
Rest of World		919,533	8.9	%		569,403	6.5	%
Total	$	10,342,426	100	%	$	8,757,352	100	%

	Nine Months Ended
	March 31,
	2023				2022
United States	$	15,997,407	57.7	%	$	14,222,605	58.4	%
Europe		9,503,235	34.3	%		8,488,722	34.8	%
Rest of World		2,243,093	8.1	%		1,660,816	6.8	%
Total	$	27,743,735	100	%	$	24,372,143	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:

	As of March 31, 2023				As of June 30, 2022
United States	$	4,041,180	59.5	%	$	3,255,976	62.0	%
Europe		2,020,602	29.7	%		1,665,111	31.7	%
Rest of World		735,458	10.8	%		330,458	6.3	%
Total	$	6,797,240	100	%	$	5,251,545	100	%

Deferred Revenue

Deferred Revenue

Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer.

Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.

Cost of Revenue

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

Foreign Currency

Foreign Currency

The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gain of $72,547 and $84,210 for the three and nine months ended March 31, 2023, respectively and losses of $29,394 and $52,619 for the three and nine months ended March 31, 2022, respectively. Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $2,256,895 and $483,232 at March 31, 2023 and June 30, 2022, respectively, was held in accounts at financial institutions located in Europe.

The following table summarizes the exchange rates used:

	Nine Months Ended		Year Ended
	March 31,		June 30,
	2023	2022	2023	2021
Period end Euro : US Dollar exchange rate	1.09	1.11	1.05	1.19
Average period Euro : US Dollar exchange rate	1.03	1.15	1.13	1.19
Period end GBP : US Dollar exchange rate	1.24	1.31	1.21	1.38
Average period GBP : US Dollar exchange rate	1.19	1.36	1.34	1.34
Period end Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05
Average period Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05

Net Income (Loss) Per Share

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted

earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2023 potentially dilutive securities include options to acquire 2,925,574 shares of common stock and unvested restricted common stock of 2,528,187. At March 31, 2022 potentially dilutive securities include options to acquire 3,249,617 shares of common stock and unvested restricted common stock of 364,675. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2022 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three and nine months ended March 31, 2023, the calculation of diluted earnings per share include unvested restricted common stock, stock options and warrants, calculated under the treasury stock method.  

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Schedule of vendor concentration risk percentage

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Vendor A	23	%	22	%	22	%	21	%
Vendor B	14	%	13	%	13	%	13	%

Schedule of revenue by geographical region

	Three Months Ended
	March 31,
	2023				2022
United States	$	5,892,424	57.0	%	$	5,027,965	57.4	%
Europe		3,530,469	34.1	%		3,159,984	36.1	%
Rest of World		919,533	8.9	%		569,403	6.5	%
Total	$	10,342,426	100	%	$	8,757,352	100	%

	Nine Months Ended
	March 31,
	2023				2022
United States	$	15,997,407	57.7	%	$	14,222,605	58.4	%
Europe		9,503,235	34.3	%		8,488,722	34.8	%
Rest of World		2,243,093	8.1	%		1,660,816	6.8	%
Total	$	27,743,735	100	%	$	24,372,143	100	%

Schedule of accounts receivable by geographical region

	As of March 31, 2023				As of June 30, 2022
United States	$	4,041,180	59.5	%	$	3,255,976	62.0	%
Europe		2,020,602	29.7	%		1,665,111	31.7	%
Rest of World		735,458	10.8	%		330,458	6.3	%
Total	$	6,797,240	100	%	$	5,251,545	100	%

Schedule of foreign currency exchange rate

The following table summarizes the exchange rates used:

	Nine Months Ended		Year Ended
	March 31,		June 30,
	2023	2022	2023	2021
Period end Euro : US Dollar exchange rate	1.09	1.11	1.05	1.19
Average period Euro : US Dollar exchange rate	1.03	1.15	1.13	1.19
Period end GBP : US Dollar exchange rate	1.24	1.31	1.21	1.38
Average period GBP : US Dollar exchange rate	1.19	1.36	1.34	1.34
Period end Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05
Average period Mexican Peso : US Dollar exchange rate	0.05	0.05	0.05	0.05

XML

Stockholders' Equity (Tables)

9 Months Ended

Mar. 31, 2023

Stockholders' Equity

Schedule of vested and unvested stock option activity

The following table summarizes vested and unvested stock option activity:

	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2022	3,182,872	$	1.79	2,999,974	$	1.75	182,898	$	2.49
Granted	200,000		2.15	—		—	200,000		2.15
Options vesting	—		—	309,486		2.27	(309,486)		2.27
Exercised	(307,298)		1.31	(307,298)		1.31	—		—
Forfeited	(150,000)		1.81	(147,917)		1.78	(2,083)		3.92
Repurchased	—		—	—		—	—		—
Outstanding at March 31, 2023	2,925,574	$	1.87	2,854,245	$	1.85	71,329	$	2.46

Schedule of valuation assumptions

The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2023 and 2022.

	Nine Months Ended
	March 31,
	2023		2022
Expected dividend yield	—	%	—	%
Risk-free interest rate	3.76	%	0.92 - 1.81	%
Expected life (in years)	5		5 - 6
Expected volatility	56	%	56	%

Schedule of additional information regarding stock options outstanding and exercisable

Additional information regarding stock options outstanding and exercisable as of March 31, 2023 is as follows:

	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	2.68	225,000
	0.77	25,000	1.39	25,000
	0.80	16,000	2.39	16,000
	0.90	15,000	2.35	15,000
	1.00	15,000	1.95	15,000
	1.05	305,000	3.40	305,000
	1.09	40,000	3.15	40,000
	1.10	105,000	2.25	105,000
	1.20	274,000	4.30	274,000
	1.59	25,000	5.12	25,000
	1.80	54,550	0.48	54,550
	1.85	16,000	0.14	16,000
	1.95	200,000	5.26	200,000
	2.10	238,767	8.87	238,767
	2.13	216,708	7.64	213,922
	2.15	200,000	9.70	200,000
	2.17	35,955	8.12	23,970
	2.19	5,000	8.81	2,083
	2.40	302,833	5.63	302,833
	2.43	61,250	8.18	51,250
	2.45	163,000	7.35	149,416
	2.49	78,435	7.17	75,076
	2.50	20,000	6.13	20,000
	2.64	30,882	8.35	18,015
	2.67	33,194	8.47	19,363
	2.99	8,000	7.12	8,000
	3.13	208,000	6.62	208,000
	3.50	8,000	6.87	8,000
	Total	2,925,574		2,854,245

Schedule of restricted common stock activity

The following table summarizes restricted common stock activity:

				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2022	400,092	$	775,453	$	2.38
Granted	2,354,834		3,478,878		1.48
Vested	(161,574)		(925,549)		2.49
Forfeited	(65,165)		(123,953)		2.15
Non-vested, March 31, 2023	2,528,187	$	3,204,829	$	1.54

XML

Organization, Nature of Business and Basis of Presentation (Details)	9 Months Ended
	Mar. 31, 2023 item subsidiary
Organization, Nature of Business and Basis of Presentation
Number of subsidiaries | subsidiary	3
Number of service offerings	2
Number of existing STM articles on the platform	80,000,000
Number of newly published STM articles each year.	1,000,000

XML

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($) item	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) item shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2022 USD ($)
FDIC insured amount	$ 250,000		$ 250,000
Cash and cash equivalents	12,132,899		$ 12,132,899		$ 10,603,175
Antidilutive securities amount | shares			2,528,187
Foreign currency transaction gain (loss)	$ 72,547	$ (29,394)	$ 84,210	$ (52,619)
Number of revenue streams | item	2		2
Employee stock options
Antidilutive securities amount | shares			2,925,574	3,249,617
Restricted Common Stock
Antidilutive securities amount | shares			2,528,187	364,675
Europe financial institutions
Cash and cash equivalents	$ 2,256,895		$ 2,256,895		$ 483,232

XML

Summary of Significant Accounting Policies - Concentrations (Details) - Content costs from vendors - Supplier Concentration	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Vendor A
Concentration percentage	23.00%	22.00%	22.00%	21.00%
Vendor B
Concentration percentage	14.00%	13.00%	13.00%	13.00%

XML

Summary of Significant Accounting Policies - Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Revenues	$ 10,342,426	$ 8,757,352	$ 27,743,735	$ 24,372,143
Percentage of revenue	100.00%	100.00%	100.00%	100.00%
Accounts receivable
Revenues			$ 6,797,240		$ 5,251,545
Percentage of revenue			100.00%		100.00%
United States
Revenues	$ 5,892,424	$ 5,027,965	$ 15,997,407	$ 14,222,605
Percentage of revenue	57.00%	57.40%	57.70%	58.40%
United States | Accounts receivable
Revenues			$ 4,041,180		$ 3,255,976
Percentage of revenue			59.50%		62.00%
Europe
Revenues	$ 3,530,469	$ 3,159,984	$ 9,503,235	$ 8,488,722
Percentage of revenue	34.10%	36.10%	34.30%	34.80%
Europe | Accounts receivable
Revenues			$ 2,020,602		$ 1,665,111
Percentage of revenue			29.70%		31.70%
Rest of World
Revenues	$ 919,533	$ 569,403	$ 2,243,093	$ 1,660,816
Percentage of revenue	8.90%	6.50%	8.10%	6.80%
Rest of World | Accounts receivable
Revenues			$ 735,458		$ 330,458
Percentage of revenue			10.80%		6.30%

XML

Summary of Significant Accounting Policies - Exchange rates (Details)	9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Euro to US Dollar
Period end exchange rate	1.09	1.11	1.05	1.19
Average period exchange rate	1.03	1.15	1.13	1.19
GBP To US Dollar
Period end exchange rate	1.24	1.31	1.21	1.38
Average period exchange rate	1.19	1.36	1.34	1.34
Mexican Peso to US Dollar
Period end exchange rate	0.05	0.05	0.05	0.05
Average period exchange rate	0.05	0.05	0.05	0.05

XML

Line of Credit (Details)	9 Months Ended
	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Jun. 30, 2022 USD ($)
Line of credit amount	$ 2,500,000
Percentage of eligible accounts receivable	80.00%
Covenants ratio	1.15
Fixed interest rate	5.00%
Interest rate on the line of credit	9.00%
Outstanding borrowings under line of credit	$ 0		$ 0
Approximate available credit	$ 2,500,000
Prime Rate [Member]
Marginal interest rate	1.00%
Silicon Valley Bridge Bank [Member]
Cash	$ 10,474,449	$ 10,832,880
Cash, Uninsured Amount	9,406,136	$ 9,738,292
Bank of America NA [Member]
Cash	750,000
PNC Bank NA [Member]
Cash	$ 905,510

XML

Stockholders' Equity - Options Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Nov. 17, 2021	Nov. 16, 2021	Nov. 17, 2020	Nov. 16, 2020	Nov. 21, 2017	Nov. 10, 2016	Nov. 09, 2016
Term number of years			5 years
Weighted average remaining contractual life of all options outstanding			5 years 8 months 15 days
Remaining contractual life for options vested and exercisable			5 years 7 months 24 days
Aggregate intrinsic value of options vested and exercisable	$ 1,060,516		$ 1,060,516
Granted (in shares)			200,000
Fair value of vested stock options	37,236	$ 296,782	$ 338,973	$ 424,450
Amount of unvested compensation related to stock options	$ 92,793		$ 92,793
Common stock issued upon exercise of stock options			307,298
Proceeds from the exercise of stock options			$ 57,500	$ 97,688
Common Stock
Common stock issued upon exercise of stock options	91,477	147,660	137,523	192,820
Proceeds from the exercise of stock options			$ 57,500
Director
Granted (in shares)			200,000
Fair value of vested stock options			$ 222,000
Employee stock options
Vesting period			3 years
Number of year(s) cliff vesting period			1 year
Term number of years			10 years
Employee stock options | 2007 Plan
Number of shares authorized under the plan										7,000,000	5,000,000
Number of shares available for grant	0		0
Employee stock options | 2017 Plan
Number of shares authorized under the plan									1,874,513
Number of shares available for grant	1,495,927		1,495,927
Employee stock options | Omnibus Incentive 2017 Plan [Member]
Number of shares authorized under the plan					6,874,513	3,374,513	3,374,513	2,374,513

XML

Stockholders' Equity - Stock option Activity (Details)	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Outstanding beginning balance (in shares) | shares	3,182,872
Granted (in shares) | shares	200,000
Exercised (in shares) | shares	(307,298)
Forfeited (in shares) | shares	(150,000)
Outstanding ending balance (in shares) | shares	2,925,574
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.79
Granted Weighted Average Exercise Price | $ / shares	2.15
Exercised Weighted Average Exercise Price | $ / shares	1.31
Forfeited Weighted Average Exercise Price | $ / shares	1.81
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.87
Vested Options [Member]
Outstanding beginning balance (in shares) | shares	2,999,974
Options vesting (in shares) | shares	309,486
Exercised (in shares) | shares	(307,298)
Forfeited (in shares) | shares	(147,917)
Outstanding ending balance (in shares) | shares	2,854,245
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.75
Options vesting Weighted Average Exercise Price | $ / shares	2.27
Exercised Weighted Average Exercise Price | $ / shares	1.31
Forfeited Weighted Average Exercise Price | $ / shares	1.78
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.85
Unvested Options [Member]
Outstanding beginning balance (in shares) | shares	182,898
Granted (in shares) | shares	200,000
Options vesting (in shares) | shares	309,486
Forfeited (in shares) | shares	(2,083)
Outstanding ending balance (in shares) | shares	71,329
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 2.49
Granted Weighted Average Exercise Price | $ / shares	2.15
Options vesting Weighted Average Exercise Price | $ / shares	2.27
Forfeited Weighted Average Exercise Price | $ / shares	3.92
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 2.46

XML

Stockholders' Equity - Valuation assumptions (Details)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Minimum
Expected life (in years)	1 year 4 months 9 days
Maximum
Expected life (in years)	2 years 7 months 2 days
Employee stock options
Risk-free interest rate	3.76%
Expected life (in years)	5 years
Expected volatility	56.00%	56.00%
Employee stock options | Minimum
Risk-free interest rate		0.92%
Expected life (in years)		5 years
Employee stock options | Maximum
Risk-free interest rate		1.81%
Expected life (in years)		6 years

XML

Stockholders' Equity - Stock options by exercise price (Details)	9 Months Ended
	Mar. 31, 2023 $ / shares shares
Options Outstanding	2,925,574
Options Exercisable	2,854,245
Range One
Option Exercise Price | $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	2 years 8 months 4 days
Options Exercisable	225,000
Range Two
Option Exercise Price | $ / shares	$ 0.77
Options Outstanding	25,000
Remaining Contractual Life (in years)	1 year 4 months 20 days
Options Exercisable	25,000
Range Three
Option Exercise Price | $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	2 years 4 months 20 days
Options Exercisable	16,000
Range Four
Option Exercise Price | $ / shares	$ 0.90
Options Outstanding	15,000
Remaining Contractual Life (in years)	2 years 4 months 6 days
Options Exercisable	15,000
Range Five
Option Exercise Price | $ / shares	$ 1.00
Options Outstanding	15,000
Remaining Contractual Life (in years)	1 year 11 months 12 days
Options Exercisable	15,000
Range Six
Option Exercise Price | $ / shares	$ 1.05
Options Outstanding	305,000
Remaining Contractual Life (in years)	3 years 4 months 24 days
Options Exercisable	305,000
Range Seven
Option Exercise Price | $ / shares	$ 1.09
Options Outstanding	40,000
Remaining Contractual Life (in years)	3 years 1 month 24 days
Options Exercisable	40,000
Range Eight
Option Exercise Price | $ / shares	$ 1.10
Options Outstanding	105,000
Remaining Contractual Life (in years)	2 years 3 months
Options Exercisable	105,000
Range Nine
Option Exercise Price | $ / shares	$ 1.20
Options Outstanding	274,000
Remaining Contractual Life (in years)	4 years 3 months 18 days
Options Exercisable	274,000
Range Ten
Option Exercise Price | $ / shares	$ 1.59
Options Outstanding	25,000
Remaining Contractual Life (in years)	5 years 1 month 13 days
Options Exercisable	25,000
Range Eleven
Option Exercise Price | $ / shares	$ 1.80
Options Outstanding	54,550
Remaining Contractual Life (in years)	5 months 23 days
Options Exercisable	54,550
Range Twelve
Option Exercise Price | $ / shares	$ 1.85
Options Outstanding	16,000
Remaining Contractual Life (in years)	1 month 20 days
Options Exercisable	16,000
Range Thirteen
Option Exercise Price | $ / shares	$ 1.95
Options Outstanding	200,000
Remaining Contractual Life (in years)	5 years 3 months 3 days
Options Exercisable	200,000
Range Fourteen
Option Exercise Price | $ / shares	$ 2.10
Options Outstanding	238,767
Remaining Contractual Life (in years)	8 years 10 months 13 days
Options Exercisable	238,767
Range Fifteen
Option Exercise Price | $ / shares	$ 2.13
Options Outstanding	216,708
Remaining Contractual Life (in years)	7 years 7 months 20 days
Options Exercisable	213,922
Range Sixteen
Option Exercise Price | $ / shares	$ 2.15
Options Outstanding	200,000
Remaining Contractual Life (in years)	9 years 8 months 12 days
Options Exercisable	200,000
Range Seventeen
Option Exercise Price | $ / shares	$ 2.17
Options Outstanding	35,955
Remaining Contractual Life (in years)	8 years 1 month 13 days
Options Exercisable	23,970
Range Eighteen
Option Exercise Price | $ / shares	$ 2.19
Options Outstanding	5,000
Remaining Contractual Life (in years)	8 years 9 months 21 days
Options Exercisable	2,083
Range Nineteen
Option Exercise Price | $ / shares	$ 2.40
Options Outstanding	302,833
Remaining Contractual Life (in years)	5 years 7 months 17 days
Options Exercisable	302,833
Range Twenty
Option Exercise Price | $ / shares	$ 2.43
Options Outstanding	61,250
Remaining Contractual Life (in years)	8 years 2 months 4 days
Options Exercisable	51,250
Range Twenty One
Option Exercise Price | $ / shares	$ 2.45
Options Outstanding	163,000
Remaining Contractual Life (in years)	7 years 4 months 6 days
Options Exercisable	149,416
Range Twenty Two
Option Exercise Price | $ / shares	$ 2.49
Options Outstanding	78,435
Remaining Contractual Life (in years)	7 years 2 months 1 day
Options Exercisable	75,076
Range Twenty Three
Option Exercise Price | $ / shares	$ 2.50
Options Outstanding	20,000
Remaining Contractual Life (in years)	6 years 1 month 17 days
Options Exercisable	20,000
Range Twenty Four
Option Exercise Price | $ / shares	$ 2.64
Options Outstanding	30,882
Remaining Contractual Life (in years)	8 years 4 months 6 days
Options Exercisable	18,015
Range Twenty Five
Option Exercise Price | $ / shares	$ 2.67
Options Outstanding	33,194
Remaining Contractual Life (in years)	8 years 5 months 19 days
Options Exercisable	19,363
Range Twenty Six
Option Exercise Price | $ / shares	$ 2.99
Options Outstanding	8,000
Remaining Contractual Life (in years)	7 years 1 month 13 days
Options Exercisable	8,000
Range Twenty Seven
Option Exercise Price | $ / shares	$ 3.13
Options Outstanding	208,000
Remaining Contractual Life (in years)	6 years 7 months 13 days
Options Exercisable	208,000
Range Twenty Eight
Option Exercise Price | $ / shares	$ 3.50
Options Outstanding	8,000
Remaining Contractual Life (in years)	6 years 10 months 13 days
Options Exercisable	8,000

XML

Stockholders' Equity - Restricted Common Stock Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Common stock issued upon exercise of stock options			307,298
Term number of years			5 years
Percentage of All Vested Shares Recipient Is Required To Hold During Employment In Order To Receive Award			75.00%
Granted (in shares)			200,000
Fair value of vested restricted common stock	$ 443,223	$ 102,452	$ 925,550	$ 446,433
Antidilutive securities amount			2,528,187
Minimum
Expected life (in years)			1 year 4 months 9 days
Maximum
Expected life (in years)			2 years 7 months 2 days
Restricted common stock
Number of shares of restricted common stock issued			2,354,834		2,829,758
Fair value of shares vested			$ 2,975,400		$ 2,215,342
Forfeited, Fair Value			$ (123,953)		$ 188,203
Forfeited, Number of shares			(65,165)		(214,324)
Amount recognized as expense related to stock issuance					$ 3,060,652
Non-vested stock	$ 3,204,829		$ 3,204,829		$ 775,453
Balance of non-vested shares	2,528,187		2,528,187		400,092
Granted Weighted Average Grant Date Fair Value			$ 1.48
Term number of years			5 years
Restricted stock to employees vested			161,574
Fair value of vested restricted common stock			$ 3,478,878		$ 4,024,308
Restricted common stock | 2017 Plan
Number of shares of restricted common stock issued			2,100,000
Restricted common stock | Minimum
Vesting period			3 years
Restricted common stock | Maximum
Vesting period			4 years
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member}
Number of shares of restricted common stock issued			100,000
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 3.00
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member} | Restricted common stock
Number of shares of restricted common stock issued			2,100,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Two [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 3.75
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Three [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 4.50
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Four [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 5.25
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Five [Member}
Vesting percentage			20.00%
Volume Weighted Average Stock Price Per Share			$ 6.00
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Six [Member}
Volume Weighted Average Stock Price Per Share			$ 5.00
Restricted stock to employees vested			40,000
Vest Over Three Year Period One | Restricted common stock
Number of shares of restricted common stock issued			229,834
Vesting period			3 years
Number of year(s) cliff vesting period			1 year
Vest Over Four Year Period | Restricted common stock
Number of shares of restricted common stock issued			25,000
Vesting period			4 years
Number of year(s) cliff vesting period			1 year
Vest Over Three and Four Year Period | Restricted common stock
Fair value of vested restricted common stock			$ 503,478

XML

Stockholders' Equity - Restricted common stock (Details) - Restricted common stock - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Non-vested, Beginning balance	400,092
Granted Number of shares	2,354,834
Vested, Number of shares	(161,574)
Forfeited, Number of shares	(65,165)	(214,324)
Non-vested, Ending balance	2,528,187	400,092
Non-vested, Beginning balance	$ 775,453
Vested, Fair Value	(925,549)
Forfeited, Fair Value	(123,953)	$ 188,203
Non-vested, Ending balance	$ 3,204,829	$ 775,453
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value	$ 2.38
Granted Weighted Average Grant Date Fair Value	1.48
Vested Weighted Average Grant Date Fair Value	2.49
Forfeited Weighted Average Grant Date Fair Value	2.15
Non-vested, Ending Balance Weighted Average Grant Date Fair Value	1.54	$ 2.38
Minimum
Stock Repurchased Average Price Per Share	1.94
Maximum
Stock Repurchased Average Price Per Share	$ 2.22

XML

Stockholders' Equity - Repurchases of our common stock (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Feb. 09, 2021
Amount of stock authorized for repurchase						$ 400,000
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs	$ 180,789		$ 180,789		$ 255,345
Average Price Paid per Share			$ 1.93
Repurchase of common stock	$ (25,827)	$ (14,241)	$ (74,556)	$ (82,053)
Publicly Announced Plans Or Programs [Member]
Share Price						$ 4.00
Common Stock
Total Number of Shares Purchased	12,785	6,086	38,585	33,402
Repurchase of common stock	$ (13)	$ (6)	$ (38)	$ (34)

XML

Acquisition (Details)			9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Asset Acquisition, Contingent Consideration [Line Items]
Payment for non-refundable deposit for asset acquisition	$ 297,450	€ 300,000	$ 297,450	$ 0
Estimated average useful life			10 years
Base Amount Plus
Asset Acquisition, Contingent Consideration [Line Items]
Contingent consideration			$ 95,689
Bonus Amount
Asset Acquisition, Contingent Consideration [Line Items]
Contingent consideration			$ 48,695